How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,194 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Bisphosphonates for treating osteoporosis

committee members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 25This guidance partially replaces TA160 and TA161. 1 1 Recommendations Recommendations The purpose of this technology appraisal was to establish at what level of absolute fracture risk bisphosphonates are cost-effective (...) a decision support aid to help support this discussion. If the person wishes to try a bisphosphonate, they should be able to start treatment with the least expensive formulation, with no other local formulary or funding restrictions. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 23 of 255 5 Appr Appraisal committee members and NICE project team aisal committee members

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

182. Cabozantinib for previously treated advanced renal cell carcinoma

Evidence 6 4 Committee discussion 7 Treatment pathway 7 Population and comparators 8 Clinical effectiveness 9 Cost effectiveness 11 End-of-life considerations 17 Results of cost-effectiveness analyses 17 Innovation 19 Pharmaceutical Price Regulation Scheme (PPRS) 2014 19 Summary of appraisal committee's key conclusions 19 5 Implementation 25 6 Appraisal committee members and NICE project team 26 Appraisal committee members 26 NICE project team 26 Cabozantinib for previously treated advanced renal cell (...) curves for all the treatments. However, the committee agreed that it was a more flexible family, which improved the curve fits to the Kaplan–Meier Cabozantinib for previously treated advanced renal cell carcinoma (TA463) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 27data on overall and progression-free survival for all treatments in the network compared with the original parametric modelling using the log

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

183. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane

committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Update information 32 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 32This guidance replaces TA371. 1 1 Recommendations Recommendations 1.1 Trastuzumab emtansine is recommended, within its marketing (...) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane T T r rastuzumab emtansine for treating astuzumab emtansine for treating HER2-positiv HER2-positive advanced breast cancer e advanced breast cancer after tr after trastuzumab and a taxane astuzumab and a taxane T echnology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

184. Adalimumab and dexamethasone for treating non-infectious uveitis

Evidence 7 4 Committee discussion 8 Clinical need and management of non-infectious uveitis 8 Clinical effectiveness 9 Cost effectiveness 12 Summary of appraisal committee's key conclusions 19 5 Implementation 27 6 Appraisal committee members and NICE project team 28 Appraisal committee members 28 NICE project team 28 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) Adalimumab and dexamethasone for treating non-infectious uveitis Adalimumab and de Adalimumab and dexamethasone for xamethasone for treating non-infectious uv treating non-infectious uveitis eitis T echnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta460 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

185. Carfilzomib for previously treated multiple myeloma

problem and treatment pathway 8 Clinical effectiveness 11 Cost effectiveness 14 Most plausible incremental cost-effectiveness ratio 17 End-of-life considerations 19 Conclusion 19 Summary of appraisal committee's key conclusions 20 5 Implementation 27 6 Appraisal committee members and NICE project team 28 Appraisal committee members 28 NICE project team 28 Carfilzomib for previously treated multiple myeloma (TA457) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk (...) treated multiple myeloma (TA457) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 27 of 296 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

186. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma

project team 19 Appraisal committee members 19 NICE project team 19 Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 201 1 Recommendations Recommendations 1.1 Olaratumab, in combination with doxorubicin, is recommended for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults, only (...) in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 206 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The technology appraisal committees are standing advisory committees of NICE. This topic was considered by members of the existing standing committees who

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

187. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia

committee members 21 NICE project team 21 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute (...) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Blinatumomab for pre Blinatumomab for previously treated viously treated Philadelphia-chromosome-negativ Philadelphia-chromosome-negative e acute lymphoblastic leukaemia acute lymphoblastic leukaemia T echnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta450 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

188. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs Certolizumab pegol and secukinumab for Certolizumab pegol and secukinumab for treating activ treating active psoriatic arthritis after e psoriatic arthritis after inadequate response to DMARDs inadequate response to DMARDs T echnology appraisal guidance Published: 24 May 2017 nice.org.uk/guidance/ta445 © NICE 2018. All rights reserved. Subject to Notice of rights (https (...) to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445) © NICE 2018. All rights

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

189. Obeticholic acid for treating primary biliary cholangitis

discussion 7 Clinical management of primary biliary cholangitis 7 Clinical effectiveness of obeticholic acid 9 Adverse events 10 Cost effectiveness 10 Innovation 15 Other considerations 15 Pharmaceutical Price Regulation Scheme (PPRS) 2014 16 Summary of appraisal committee's key conclusions 16 5 Implementation 22 6 Appraisal committee members and NICE project team 23 Appraisal committee members 23 NICE project team 23 Obeticholic acid for treating primary biliary cholangitis (TA443) © NICE 2018. All (...) of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to Ruth Nasr on 020 3805 7531 or email ruth.nasr@interceptpharma.com. Obeticholic acid for treating primary biliary cholangitis (TA443) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 22 of 246 6 Appr Appraisal committee me aisal committee members and NICE project team mbers and NICE

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

190. Apremilast for treating active psoriatic arthritis

Clinical effectiveness 9 Cost effectiveness 11 Rapid review 18 Summary of appraisal committee's key conclusions 22 5 Implementation 29 6 Appraisal committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Apremilast for treating active psoriatic arthritis (TA433) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 31This guidance replaces TA372. 1 1 Recommendations Recommendations (...) Apremilast for treating active psoriatic arthritis Apremilast for treating activ Apremilast for treating active psoriatic e psoriatic arthritis arthritis T echnology appraisal guidance Published: 22 February 2017 nice.org.uk/guidance/ta433 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

191. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

of appraisal committee's key conclusions 22 5 Implementation 30 6 Appraisal committee members, guideline representatives and NICE project team 31 Appraisal committee members 31 NICE project team 31 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 321 1 Recommendations (...) Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation Ibrutinib for pre Ibrutinib for previously treated chronic viously treated chronic lymphocytic leukaemia and untreated lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p chronic lymphocytic leukaemia with 17p deletion or TP53 mutation deletion or TP53 mutation T echnology appraisal guidance Published: 25 January 2017 nice.org.uk

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

192. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

guidance 241) 19 Cancer Drugs Fund partial reconsideration of NICE technology appraisal guidance 241 19 Summary of appraisal committee's key conclusions 21 5 Implementation 31 6 Appraisal committee members and NICE project team 32 Appraisal committee members 32 NICE project team 32 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia Dasatinib, nilotinib and high-dose Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or imatinib for treating imatinib-resistant or intoler intolerant chronic m ant chronic my yeloid leukaemia eloid leukaemia T echnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425 © NICE 2018. All rights reserved. Subject to Notice of rights

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

193. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens

members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 25This guidance replaces TA250. This guidance should be read in conjunction with TA515. 1 1 Recommendations Recommendations 1.1 Eribulin is recommended as an option (...) with locally advanced or metastatic breast cancer, whose disease has progressed after at least 2 chemotherapy regimens. The committee concluded that eribulin is particularly valuable, and has been more widely used, for HER2-negative disease because this has fewer treatment options. It also recognised that the availability of additional treatment options for advanced disease would be valued by patients and their families. 4.1 to 4.3 The technology The technology Eribulin for treating locally advanced

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

194. Hereditary Colorectal Cancer Syndromes Endorsement of the Familial Risk?Colorectal Cancer ESMO Guideline

and added a few qualifying statements. Recommendations Approximately 5% to 6% of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary (...) testimony. In accordance with these procedures, the majority of the members of the panel did not disclose any such relationships (see Author Disclosures of Potential Conflicts of Interest section at the end of the article). CLINICAL QUESTIONS AND TARGET POPULATION Section: The ESMO guidelines addressed clinical questions on prevention, screening, genetics, treatment, and management for people at risk for LS, APC -associated FAP, AFAP, MAP, and familial CRC type X. SUMMARY OF ESMO GUIDELINES DEVELOPMENT

Full Text available with Trip Pro

2014 American Society of Clinical Oncology Guidelines

195. Lojuxta (lomitapide) - familial hypercholesterolaemia

g/l and arterial disease. Individual diagnosis of familial hypercholesterolaemia is the first step in the investigation and management of a family at high risk of cardiovascular disease. It should be done as early as possible, at the silent and reversible phase of arterial disease. Severe familial hypercholesterolaemia is treated by centres specialising in hereditary metabolic disorders. The prognosis is a direct function of the patient's age, LDL-C level and ongoing arterial exposure to a fixed (...) treatments indicated in combination with lipid-lowering treatments at maximum doses in patients with uncontrolled HoFH. The other available medicines for treating HoFH are the following: NAME (INN) Company Same TC* Yes / No Indication Date of opinion AB / IAB (Wording) Reimburs ement Yes/No CRESTOR (rosuvastatin) Astra Zeneca No Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid- lowering treatments (especially LDL apheresis) or if such treatments are not appropriate. 02/02

2014 Haute Autorite de sante

196. Effectiveness of Family and Caregiver Interventions on Patient Outcomes among Adults with Cancer or Memory-Related Disorders

evidence assessing whether family involved interventions improve patient outcomes (i.e., efficacy) and whether specific family involved interventions are better than alternative ones (i.e., specificity or comparative effectiveness). We specifically examined the effects of family-involved interventions on the patients, not on the family members. We assessed if there is evidence that interventions targeted at family members only or both family members and adult care recipients improve the patients (...) ’ outcomes. We limited our focus to family members caring for those with cancer and memory-related conditions since the majority of studies examine one of these two conditions. This project was nominated by Sonja Batten, PhD, Office of Mental Health Services. The key questions and scope were refined with input from a technical expert panel. We addressed the following key questions: Key Question #1. What are the benefits of family and caregiver psychosocial interventions for adult patients with cancer

2013 Veterans Affairs Evidence-based Synthesis Program Reports

197. Working with Families to Promote Safe Sleep for Infants 0-12 Months of Age

-12 Months of Age PRACTICE RECOMMENDATIONS G LEVEL OF EVIDENCE 3.0 Implementation ...con’t 3.8 Provide smoking cessation counseling before, during, and after pregnancy to women, family members and other caregivers identified as tobacco users . III 3.9 Encourage women, family members and other caregivers to promote a smoke-free environment during and after pregnancy . III 3.10 Provide health education about the risks associated with SIDS and alcohol and substance use and their potential effect (...) , Kangaroo Mother Care Educator Childbirth and Postpartum Professional Association (CAPPA) Canada Hamilton, Ontario Helen Tindale, RN, BScN, PHN Public Health Nurse (R) Child and Family Health Division/Healthy Babies Healthy Children Region of Waterloo Public Health Cambridge, Ontario Registered Nurses’ Association of Ontario Expert Panel *(R) = Retired Declarations of interest and confidentiality were made by all members of the RNAO Expert Panel. Further details are available from the Registered Nurses

2014 Registered Nurses' Association of Ontario

198. Increased expression of IL-6 family members in tendon pathology (PubMed)

Increased expression of IL-6 family members in tendon pathology Histological examination of pathological tendon generally does not reveal signs of inflammation. However, the inflammatory cytokine IL-6 has been shown to be expressed in ruptured rotator cuff tendon. The aim of this study was to investigate the expression of IL-6 family members in painful posterior tibialis tendon (PTT) and in painful and ruptured Achilles tendon (AT) compared with normal tendon.AT samples were obtained from (...) cadavers (normal) or from patients undergoing surgical procedures to treat chronic painful tendinopathy or ruptured tendon. PTT samples were obtained from patients undergoing surgery for other reasons (normal) and from patients with PTT dysfunction (painful). Total RNA was extracted and mRNA expression was analysed by quantitative real-time PCR.Collagen type I α-chain I (COL1A1) expression was increased in both painful PTT and AT compared with normal. Ciliary neurotrophic factor levels were increased

Full Text available with Trip Pro

2012 Rheumatology (Oxford, England)

199. Frequency of Asymptomatic Disease Among Family Members With Noncompaction Cardiomyopathy. (PubMed)

symptoms and signs, but most (28 of 41) were asymptomatic. Most subjects with NCC had mild to moderate left ventricular dysfunction (n = 29, 71%). After a median follow-up of 55 months (interquartile range 43 to 93), most remained asymptomatic. Four family members were treated with prophylactic implantable cardioverter-defibrillator placement and 23 of those with NCC were treated with drugs, including angiotensin-converting enzyme inhibitors (41%), β blockers (34%), and anticoagulants (17 (...) Frequency of Asymptomatic Disease Among Family Members With Noncompaction Cardiomyopathy. Noncompaction cardiomyopathy (NCC) is a primary cardiomyopathy characterized by an excessively prominent trabecular meshwork and deep intertrabecular recesses of the left ventricular walls. Most cases are inherited, with a dominant inheritance pattern. The aim of the present study was to determine the prevalence and clinical characteristics of cardiomyopathies in the close relatives of patients with NCC

2012 American Journal of Cardiology

200. The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01616862 Recruitment Status : Completed First Posted : June 12, 2012 Last Update Posted : June 2, 2015 Sponsor: Zafer

2012 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>